X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3186) 3186
Publication (568) 568
Patent (68) 68
Book Chapter (21) 21
Book / eBook (12) 12
Book Review (6) 6
Web Resource (3) 3
Conference Proceeding (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1489) 1489
middle aged (932) 932
oncology (902) 902
aged (842) 842
adult (837) 837
female (834) 834
index medicus (834) 834
male (832) 832
hematology (785) 785
aged, 80 and over (475) 475
treatment outcome (471) 471
prognosis (417) 417
article (380) 380
adolescent (342) 342
leukemia (332) 332
antineoplastic agents - therapeutic use (319) 319
cancer (319) 319
chronic myelogenous leukemia (299) 299
therapy (286) 286
antineoplastic combined chemotherapy protocols - therapeutic use (280) 280
abridged index medicus (275) 275
imatinib mesylate (267) 267
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (255) 255
remission induction (242) 242
leukemia, myeloid, acute - drug therapy (219) 219
acute myeloid-leukemia (216) 216
research (211) 211
hemic and lymphatic diseases (209) 209
benzamides (206) 206
survival analysis (203) 203
care and treatment (200) 200
survival (199) 199
chemotherapy (198) 198
young adult (197) 197
chronic myeloid leukemia (195) 195
chronic myeloid-leukemia (191) 191
survival rate (185) 185
pyrimidines - therapeutic use (183) 183
mutation (179) 179
acute myeloid leukemia (172) 172
disease-free survival (170) 170
hematology, oncology and palliative medicine (168) 168
protein kinase inhibitors - therapeutic use (162) 162
follow-up studies (156) 156
piperazines - therapeutic use (155) 155
acute myelogenous leukemia (147) 147
acute lymphoblastic-leukemia (144) 144
drug administration schedule (139) 139
myelodysplastic syndromes (139) 139
retrospective studies (139) 139
cytarabine - administration & dosage (136) 136
leukemia, myelogenous, chronic, bcr-abl positive - genetics (133) 133
dasatinib (132) 132
imatinib (132) 132
myelodysplastic syndromes - drug therapy (129) 129
risk factors (129) 129
antineoplastic agents - adverse effects (127) 127
drug therapy (126) 126
philadelphia chromosome (124) 124
myelodysplastic syndrome (122) 122
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (120) 120
recurrence (120) 120
antineoplastic combined chemotherapy protocols - adverse effects (116) 116
leukemia, myeloid, acute - genetics (113) 113
leukemia, myeloid, acute - mortality (112) 112
dose-response relationship, drug (111) 111
protein-tyrosine kinases - antagonists & inhibitors (111) 111
antineoplastic agents - administration & dosage (108) 108
analysis (105) 105
aml (102) 102
bcr-abl (98) 98
cytarabine (98) 98
patients (98) 98
drug resistance, neoplasm (97) 97
cells (96) 96
interferon-alpha (96) 96
pyrimidines - administration & dosage (95) 95
time factors (95) 95
leukemia, myelogenous, chronic, bcr-abl positive - pathology (92) 92
patient outcomes (92) 92
fusion proteins, bcr-abl - genetics (91) 91
expression (89) 89
minimal residual disease (89) 89
salvage therapy (89) 89
acute disease (87) 87
transplantation (85) 85
diagnosis (83) 83
disease progression (83) 83
dosage and administration (83) 83
health aspects (83) 83
pyrimidines - adverse effects (82) 82
cml (81) 81
genetic aspects (81) 81
acute lymphoblastic leukemia (80) 80
neoplasms (79) 79
tyrosine kinase inhibitor (79) 79
chronic lymphocytic-leukemia (78) 78
kaplan-meier estimate (77) 77
leukemia, myeloid, chronic-phase - drug therapy (77) 77
mutations (77) 77
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Online Resources - Online (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3288) 3288
French (30) 30
German (12) 12
Korean (4) 4
Spanish (2) 2
Chinese (1) 1
Hungarian (1) 1
Japanese (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 17, pp. 1674 - 1675
Journal Article
Cancer, ISSN 0008-543X, 11/2018, Volume 124, Issue 22, pp. 4301 - 4313
Historically, progress in leukemia research has been slow, but it has accelerated recently as a result of understanding the pathophysiology of leukemias and... 
targeted | leukemias | cure | therapy | treatments | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | ACUTE MYELOID-LEUKEMIA | TRANS-RETINOIC ACID | HAIRY-CELL LEUKEMIA | ONCOLOGY | CORE-BINDING-FACTOR | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | TERM-FOLLOW-UP | MINIMAL RESIDUAL DISEASE | ACUTE PROMYELOCYTIC LEUKEMIA | Historical account | Leukemia
Journal Article
Ca : a Cancer Journal for Clinicians, ISSN 0007-9235, 03/2018, Volume 68, Issue 2, p. 153
“Financial toxicity” has now become a familiar term used in the discussion of cancer drugs, and it is gaining traction in the literature given the high price... 
Health care expenditures | Toxicity | Coping | Health care access | Cancer therapies | Patients | Cancer
Journal Article
2004, Hematology/oncology clinics of North America, Volume 18, no. 3., xvi p., p. [525]-782
Book
Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 13, pp. 2398 - 2403
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Journal Article
Nature Reviews. Clinical Oncology, ISSN 1759-4774, 10/2016, Volume 13, Issue 10, p. 650
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2386 - 2398
Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from... 
MEDICINE, GENERAL & INTERNAL | IDH2 MUTATIONS | METAANALYSIS | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | DIFFERENTIATION | INHIBITOR | Glycine - analogs & derivatives | Recurrence | Follow-Up Studies | Glycine - adverse effects | Cell Count | Humans | Middle Aged | Pyridines - pharmacokinetics | Drug Resistance, Neoplasm | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Pyridines - adverse effects | Enzyme Inhibitors - pharmacokinetics | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Glycine - administration & dosage | Enzyme Inhibitors - adverse effects | Glycine - pharmacokinetics | Pyridines - administration & dosage | Administration, Oral | Isocitrate Dehydrogenase - genetics | Survival Rate | Remission Induction | Leukemia, Myeloid, Acute - mortality | Adolescent | Aged | Mutation | Hemoglobins - analysis | Leukemia, Myeloid, Acute - genetics | Usage | Myelocytic leukemia | Gene mutations | Physiological aspects | Genetic aspects | Nonlymphoid leukemia | Research | Drug therapy | Isocitrate dehydrogenase | Risk factors | Thrombocytopenia | Myeloid leukemia | Leukemia | FDA approval | Cancer therapies | Patients | Investigations | Leukocytosis | Collaboration | Point mutation | Remission | Acute myeloid leukemia | Drug dosages | Neutropenia | Tumors
Journal Article
1998, Basic and clinical oncology, ISBN 9780824798864, Volume 14., ix, 572
Book
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 9, pp. 2061 - 2068
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2009, Volume 84, Issue 2, pp. 161 - 169
Journal Article